1Lavelle F, Bissery MC, Andre S, et al. Preclinical evaluation of CPT11 and its active metabolite SN-38[J]. Semin Oncol, 1996, 23(1 Suppl 3):11-20.
2Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic coloreetal cancer[J].J Clin Oncol, 1996,14(3):709-715.
3Pitot HC,Wender DB,O'connell MJ, et al. Phase Ⅱ trial of irinotecan in patients with metastatic colorectal carcinoma [J]. J Clin Oncol, 1997,15(8):2910-2919.
4Masuda N. Establishment of the standard regimen for non-small-cell lung cancer in Japan[J]. Oncolngy,2001,15(1 Suppl 1):13-18.
5Jagasia MH, Langer CJ, Johnson DH, et al. Weekly irinotecan and cisplatin in advanced non-small-cell lung cancer: a multicenter phase Ⅱ study[J]. Clin Cancer Res, 2001, 7(1):68-73.
6Ueoka H,Tanimoto M,Kiura K, et al. Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer:a phase Ⅱ study of Okayama Lung Cancer Study Group[J]. Br J Cancer,2001,85(1):9-13.
7Takeda K, Negoro S, Takifuji N, et al. Dose escalation study of irinotecan combined with earboplatin for advanced non-small-cell lung cancer[J]. Cancer Chemother Pharmacol, 2001,48(2):104-108.
8Rigas JR. Non-platinum based combination chemotherapy:phase Ⅰ and Ⅱ trials of docetaxel plus gemcitabine, vinorelbine,or irinotecan [J]. Semin Oncol, 2001, 28(3 Suppl 9):15-20.
9Bunn PA jr. Triplet combination chemotherapy and targeted therapy regimens[J]. Oncology, 2001,15(3 Suppl 6):26-32.
10Socinski MA, Sandier AB, Miller LL, et al. Phase Ⅰtrial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer [J]. J Clin Oncol, 2001,19(4):1078-1087.
